OMAHA- Volunteers at the University of Nebraska Medical Center enrolled in a new clinical trial to test the safety and effectiveness of another vaccine candidate for COVID-19 on Tuesday morning. The plan is to enroll 1,000 people in the clinical trial to test the Novavax Inc. trial that will enroll 30,000 people in total. There has been so much interest in the trial that the university is adding appointments as soon as the morning of the 31st.

There are two main groups of interested people. The first group is that of people who know they will not receive the other vaccines for months and are willing to take the chance of receiving an ineffective one if it means there is also a chance it works. The other is that of people who want to avoid the side effects they have heard of from the other vaccines. Dr. Diane Florescu says people are also wanting to help just so that more vaccines can be available for everyone. People are wanting to help.

As of Monday, 21,419 doses of the Moderna and Pfizer vaccines had been administered in the state and nearly 50,000 have arrived.

Dr. Anthony Fauci says in order to vaccinate enough people, more than two companies will need to be manufacturing a vaccine. This vaccine is made differently from the other vaccines. Pfizer and Moderna were the first two companies to use a new technology called mRNA whereas the Novavax vaccine relies on spike protein found on coronavirus's surface. This vaccine also requires to shots given roughly three weeks apart.

For information to enroll, click HERE

Read the full article by clicking HERE